Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI chatbot could help gynecologic cancer survivors reclaim sexual health

NCT ID NCT07794098

Symptom relief Sponsor: Chang Gung Memorial Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 31, 2026 · Last updated Sep 01, 2026 · Updated 1 time

Summary

Researchers in Taiwan are testing LillyBot, an AI chatbot that provides personalized sexual health education and consultation for women who have had gynecologic cancer. The trial will enroll 90 survivors and compare two versions of the system, one with proactive nurse contact and one with contact only when safety issues arise. Participants will be followed for three months to see if the chatbot reduces sexual distress, boosts knowledge, and improves attitudes and satisfaction. The goal is to offer a private, accessible way to support sexual well-being after cancer treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
An AI chatbot-based sexual health information and consultation system called LillyBot, with nurse researcher contact
What this could lead to
If it works, this could give gynecologic cancer survivors a private, on-demand way to learn about and manage sexual health after treatment, easing distress and improving well-being.
What could go wrong
This is an early-stage trial with 90 participants, so results may not apply to all survivors. The chatbot's advice depends on the information it is given, and it cannot replace personalized medical care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 90 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2026

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 to 70 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Women diagnosed with gynecologic cancer within 6 months prior to enrollment. Women receiving cancer treatment at the recruiting hospital. Aged 20 to 70 years, inclusive. Have a regular partner. Possesses and is able to use an internet-enabled mobile device (such as a smartphone or iPad). Able to clearly communicate and read/write in Mandarin or Taiwanese. Exclusion Criteria: History of other malignant tumors. Intellectual disability or mental disorders.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gynecologic cancer survivors are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Coitus female reproductive organ cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Gynecologic cancer survivors Sexual and reproductive health

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Cheng Gung Memorial Hospital

    RECRUITING

    Taoyuan, Guishan, 333, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.